MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-15-2022
Allena Pharmaceuticals ROA Ratio 2011-2026 | ALNA
Annual ROA Ratio Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -140.01 | -84.37 | -138.79 | -54.65 | -22.49 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.49 | -140.01 | -88.06 |
Quarterly ROA Ratio Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -149.07 | -131.53 | -160.46 | -159.24 | -133.63 | -130.16 | -121.85 | -93.63 | -84.37 | -91.32 | -109.66 | -124.8 | -138.79 | -120.22 | -95.84 | -76.05 | -54.65 | -46.85 | -37.13 | -28.68 | -22.49 | -28.13 | -35.67 | -30.86 | -24.97 | -12.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.4 | -160.46 | -86.25 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.49 | 0.58 % | $ 1.04 B |  Canada |
 |
Frequency Therapeutics
FREQ
|
-103.31 | - | - | $ 528 M | USA |
 |
argenx SE
ARGX
|
-14.32 | $ 700.45 | -1.19 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.6 | 1.41 % | $ 8.66 B |  Australia |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 7.81 | -2.01 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 225.98 | -1.32 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-37.22 | $ 4.13 | -5.06 % | $ 105 M |  Schweiz |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-101.11 | - | 10.36 % | $ 9.8 M | USA |
 |
BioCardia
BCDA
|
-387.38 | $ 1.26 | -0.79 % | $ 26.7 M | USA |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
-30.55 | $ 14.2 | -0.7 % | $ 208 M | USA |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 91.19 | 1.21 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.44 | -1.37 % | $ 367 M | Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 6.68 | -4.57 % | $ 183 M |  Israel |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-50.64 | - | - | $ 521 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 7.92 | 1.67 % | $ 1.31 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.54 | -5.22 % | $ 16 M | USA |
 |
Certara
CERT
|
-0.1 | $ 6.67 | 1.6 % | $ 1.07 B | USA |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 3.6 | -4.0 % | $ 7.83 B | Israel |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-634.44 | - | -2.5 % | $ 5.88 M | USA |